Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting ...
If you have been watching Gilead Sciences lately, you know it's been a whirlwind, and not in a way that will leave you dizzy, ...
Gilead (GILD) stock is in focus as the company halts a Phase 1 trial for its long-acting HIV injectable GS-1219, spotlighting ...
CVS Caremark, the largest PBM in the U.S., tells activists Gilead needs to lower the price of its new HIV drug to get on ...
Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for ...
Pricing issues have taken precedence as CVS Health’s (NYSE:CVS) pharmacy benefit manager, CVS Caremark, continues to hold off ...
Health Canada has granted conditional approval for Gilead Sciences’ Lyvdelzi (seladelpar) for adults with primary biliary ...
Stocktwits on MSN
Gilead Stock Ignites Retail-Trader Frenzy As Trodelvy Cuts Breast Cancer Progression Risk By 38% In Phase 3 Trial
Retail buzz spiked around Gilead Sciences Inc. after the biotech firm on Sunday revealed new data showing that its cancer ...
Gilead Sciences and Arcus Biosciences’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to ...
After tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state ...
Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until April 2036.
Susan Galbraith, Ph.D., AZ’s oncology R&D chief, attributed Datroway’s strong efficacy to its ADC construct, specifically its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback